Skip to content
Login Register

#aminopterin

3 public questions tagged with this topic.

Immunological Applications

Aminopterin in HAT medium functions by:

Aminopterin classifies as antifolate antimetabolite structurally analogous to folic acid with pteridine ring substitution preventing enzymatic reduction. Dihydrofolate reductase normally catalyzes NADPH dependent reduction of dihydrofolate to tetrahydrofolate, central one-carbon carrier crucial for biosynthesis. Tetrahydrofolate derivatives required at two distinct steps: 10-formyl tetrahydrofolate donates formyl groups to glycinamide ribonucleotide transformylase and aminoimidazole carboxamide ribonucleotide transformylase in de novo purine pathway synthesizing inosine monophosphate precursor to adenine and guanine nucleotides, and 5,10-methylene tetrahydrofolate provides methyl group to thymidylate synthase converting deoxyuridine monophosphate to thymidine monophosphate essential for DNA replication. Aminopterin competitive inhibition depletes all tetrahydrofolate pools, halts purine and thymidine triphosphate production, cellular ATP drops, AMPK activated, p53 stabilization triggers apoptosis within hours. Rapidly proliferating lymphocytes depend heavily on de novo route because salvage alone insufficient during S phase. Provision of hypoxanthine and thymidine allows salvage-competent cells to circumvent block via HGPRT and TK, explaining selective toxicity exploited in hybridoma selection and historically in cancer chemotherapy similar to methotrexate.

Ref: Goodman & Gilman Pharmacol 13th ed DHFR antifolate; Lodish MBoC 9th ed Fig 7-32 aminopterin blocks de novo purine thymidylate.

View Details
Immunological Applications

Aminopterin in HAT medium functions by:

Antibody specificity arises exquisite three-dimensional complementarity between paratope heavy light chain variable domains epitope antigen surface determining binding free energy selectivity. Variable domains each contribute three complementarity-determining regions CDR1 CDR2 CDR3 loops supported conserved framework beta sheet Ig fold creating pocket groove protruding loop accommodating antigen features charged arginine aspartate hydrophobic tryptophan phenylalanine patches hydrogen bond donors carbohydrate. Binding stabilized hydrogen bonds CDR backbone carbonyl antigen side chain salt bridges arginine aspartate van der Waals contacts burying 600-900 square angstrom entropic gain displacing ordered water. Equilibrium dissociation constants after affinity maturation involving activation-induced cytidine deaminase mediated somatic hypermutation point mutations rate 10^-3 per base division selection improved binding germinal center dark zone light zone cycle follicular dendritic cell antigen presentation T follicular helper CD40 ligand signals reach picomolar 10^-11 M. Specific antibody discriminates closely related antigens differing single amino acid HER1 vs HER2 despite 40 percent homology or dopamine vs norepinephrine preventing cross-reactivity contributing safety therapeutic monoclonal targeting CD20 without depleting CD22 or HER2 without affecting EGFR. Specificity underpins diagnostic accuracy toxin neutralization blocking receptor interaction therapeutic targeting.

Ref: Janeway Antibody Specificity CDR Structure Affinity Chapter 5; NCBI Antibody Antigen Recognition Principles; Alberts Immunoglobulin Variable Region Specificity Chapter 24.

View Details
Immunological Applications

HAT medium contains:

HAT medium intelligent metabolic selection exploiting two distinct pathways nucleotide biosynthesis de novo synthesis requiring tetrahydrofolate one-carbon donor and salvage reusing preformed purines pyrimidines. Aminopterin potent folic acid analog competitively inhibits dihydrofolate reductase converting dihydrofolate tetrahydrofolate Ki 0.03 nM blocking regeneration tetrahydrofolate required thymidylate synthase converting dUMP dTMP purine enzymes GAR transformylase AICAR transformylase shutting de novo purine thymidine synthesis hours. Cell survival then depends entirely salvage enzymes HPRT converting hypoxanthine supplied IMP thymidine kinase phosphorylating thymidine TMP. Myeloma partners deliberately selected HPRT-negative mutants via resistance 8-azaguanine analog kills HPRT-proficient cells incorporating toxic nucleotide cannot utilize hypoxanthine therefore die aminopterin presence 48h. Primary B cells naturally expire short lifespan 3 days. Only heterokaryons inheriting functional HPRT gene B cell immortal proliferation program myeloma proliferate forming visible colonies 10-14 days post fusion counted inverted microscope. Optimized formulation hypoxanthine 100 uM aminopterin 0.4 uM thymidine 16 uM RPMI 1640 20 percent FBS supporting selective growth hybridomas.

Ref: Littlefield Science 1964 HAT Selection Classic; Janeway Immunobiology HAT Composition Components Chapter 2; Lodish Cell Culture HAT Selection Principle Media.

View Details